Your shopping cart is currently empty

Pan-RAS-IN-1 is an inhibitor of pan-Ras. It disrupts the interaction of Ras proteins and their effectors.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $73 | In Stock | In Stock | |
| 2 mg | $98 | In Stock | In Stock | |
| 5 mg | $147 | In Stock | In Stock | |
| 10 mg | $228 | In Stock | In Stock | |
| 25 mg | $463 | In Stock | In Stock | |
| 50 mg | $695 | In Stock | In Stock | |
| 100 mg | $987 | In Stock | In Stock | |
| 500 mg | $1,980 | 8-10 weeks | 8-10 weeks | |
| 1 mL x 10 mM (in DMSO) | $233 | In Stock | In Stock |
| Description | Pan-RAS-IN-1 is an inhibitor of pan-Ras. It disrupts the interaction of Ras proteins and their effectors. |
| In vitro | Pan-RAS-IN-1 is cytostatic, possibly due to pan-RAS inhibition at some concentrations. Pan-RAS-IN-1 is evaluated in primary T cell acute lymphoblastic leukemia (T-ALL) cells. Selective lethality is observed, with mutant NRAS cells retaining only 20%-40% viability after 5 μM treatment. Pan-RAS-IN-1 binds to KRasG12D-GppNHp with an affinity of less than 20 μM. Pan-RAS-IN-1 binds to Ras proteins and exhibits lethality in cells partially dependent on the expression of Ras proteins. The potency of pan-RAS-IN-1 correlates with the degree of dependency on the mutated isoform over a 5-fold concentration range [1]. |
| In vivo | Pan-RAS-IN-1-treated mice show decreased tumor pERK levels compared with vehicle-treated mice. Pan-RAS-IN-1 administration causes inhibition of tumor growth over 15 days of treatment. A modest increase in cleaved caspase-3 is also observed, showing that pan-RAS-IN-1 has the capacity to induce caspase activation in this model[1]. |
| Molecular Weight | 717.65 |
| Formula | C36H41Cl2F3N6O2 |
| Cas No. | 1835283-94-7 |
| Smiles | NC1(CCNCC1)C(=O)NCCCn1cc(-c2ccc(OC(F)(F)F)cc2)c2cc(CN3CCN(Cc4c(Cl)cccc4Cl)CC3)ccc12 |
| Relative Density. | 1.38 g/cm3 (Predicted) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 50 mg/mL (69.67 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (2.79 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | ||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||
DMSO
| |||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.